Patient-Controlled Methylphenidate for Cancer Fatigue: A Double-Blind, Randomized, Placebo-Controlled Trial
- 1 May 2006
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 24 (13), 2073-2078
- https://doi.org/10.1200/jco.2005.02.8506
Abstract
To evaluate the effectiveness of patient-controlled methylphenidate as compared with placebo in cancer patients with fatigue, as measured by the Functional Assessment for Chronic Illness Therapy-Fatigue (FACIT-F). Patients with a fatigue score of at least 4 on a scale of 0 to 10 (0 = no fatigue, 10 = worst possible fatigue) and hemoglobin level of at least 10 g/dL were included. Patients were randomly assigned to receive 5 mg methylphenidate or placebo every 2 hours as needed (maximum of four capsules a day), for 7 days. Patients completed a daily diary including study drug record and fatigue intensity. A research nurse telephoned patients daily to assess toxicity and fatigue level. All patients were offered open-label methylphenidate for 4 weeks. FACIT-F and the Edmonton Symptom Assessment System (ESAS) were assessed at baseline, and days 8, 15, and 36. The FACIT-F fatigue subscore on day 8 was considered the primary end point. Of 112 patients randomly assigned, 52 patients in the methylphenidate and 53 in the placebo group were assessable for analysis. Fatigue intensity improved significantly on day 8 in both the methylphenidate and placebo groups. However, there was no significant difference in fatigue improvement by FACIT-F (P = .31) or ESAS (P = .14) between groups. In open-label phase, fatigue intensity maintained low as compared with baseline. No significant toxicities were observed. Both methylphenidate and placebo resulted in significant symptom improvement. Methylphenidate was not significantly superior to placebo after 1 week of treatment. Longer study duration is justified. The role of daily telephone calls from a research nurse should be explored as a palliative care intervention.Keywords
This publication has 22 references indexed in Scilit:
- The correlation between fatigue, physical function, the systemic inflammatory response, and psychological distress in patients with advanced lung cancerCancer, 2005
- Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioidsCancer, 2004
- Patient-Controlled Methylphenidate for the Management of Fatigue in Patients With Advanced Cancer: A Preliminary ReportJournal of Clinical Oncology, 2003
- Patient-Related Barriers to Fatigue Communication: Initial Validation of the Fatigue Management Barriers QuestionnaireJournal of Pain and Symptom Management, 2002
- Fatigue in patients with advanced cancer: A reviewInternational Journal of Gynecologic Cancer, 2002
- A phase II study of methylphenidate for depression in advanced cancerAmerican Journal of Hospice and Palliative Medicine®, 2001
- Pharmacokinetics and Clinical Effectiveness of MethylphenidateClinical Pharmacokinetics, 1999
- Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement systemJournal of Pain and Symptom Management, 1997
- Neuropsychological effects of methylphenidate in patients receiving a continuous infusion of narcotics for cancer painPain, 1992
- O.80 Abnormal carbohydrate metabolism in lung cancer patients: Influence of hydrazine sulfateClinical Nutrition, 1983